Back to Browse Journals » Clinical Interventions in Aging » Volume 3 » Issue 3

Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women

Authors Irene Lambrinoudaki, Sophia Vlachou, Fotini Galapi, Dimitra Papadimitriou, K Papadias

Published 12 September 2008 Volume 2008:3(3) Pages 445—451


Irene Lambrinoudaki, Sophia Vlachou, Fotini Galapi, Dimitra Papadimitriou, K Papadias

2nd Department of Obstetrics and Gynecology, University of Athens, Aretaieio Hospital, Greece

Abstract: Zoledronic acid is a nitrogen-containing, third-generation bisphosphonate that has recently been approved for the treatment of postmenopausal osteoporosis as an annual intravenous infusion. Zoledronic acid is an antiresorptive agent which has a high affinity for mineralized bone and especially for sites of high bone turnover. Zoledronic acid is excreted by the kidney without further metabolism. Zoledronic acid administered as a 5 mg intravenous infusion annually increases bone mineral density in the lumbar spine and femoral neck by 6.7% and 5.1% respectively and reduces the incidence of new vertebral and hip fractures by 70% and 41% respectively in postmenopausal women with osteoporosis. Most common side effects are post-dose fever, flu-like symptoms, myalgia, arthralgia, and headache which usually occur in the first 3 days after infusion and are self-limited. Rare adverse effects include renal dysfunction, hypocalcemia, atrial fibrillation, and osteonecrosis of the jaw.

Keywords: zoledronic acid, postmenopausal osteoporosis, bisphosphonate

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Readers of this article also read:

Varicella zoster virus-associated anterior uveitis in a seronegative adult without a history of chickenpox

Mine I, Ishikawa S, Takeuchi M

Clinical Ophthalmology 2015, 9:399-402

Published Date: 26 February 2015

Non-adherence to topical treatments for actinic keratosis

Shergill B, Zokaie S, Carr AJ

Patient Preference and Adherence 2014, 8:35-41

Published Date: 17 December 2013

Dual-channel functional electrical stimulation improvements in speed-based gait classifications

Springer S, Laufer Y, Becher M, Vatine JJ

Clinical Interventions in Aging 2013, 8:271-277

Published Date: 28 February 2013

Potential role of odanacatib in the treatment of osteoporosis


Clinical Interventions in Aging 2012, 7:235-247

Published Date: 12 July 2012

In vitro evaluation of anticancer nanomedicines based on doxorubicin and amphiphilic Y-shaped copolymers

Li D, Ding JX, Tang ZH, Sun H, Zhuang XL, Xu JZ, Chen XS

International Journal of Nanomedicine 2012, 7:2687-2697

Published Date: 31 May 2012

Concentration- and time-dependent response of human gingival fibroblasts to fibroblast growth factor 2 immobilized on titanium dental implants

Ma Q, Wang W, Chu PK, Mei S, Ji K, Jin L, Zhang Y,

International Journal of Nanomedicine 2012, 7:1965-1976

Published Date: 17 April 2012

The effect of phosphatidylserine-containing omega-3 fatty acids on memory abilities in subjects with subjective memory complaints: a pilot study

Yael Richter, Yael Herzog, Tzafra Cohen, et al

Clinical Interventions in Aging 2010, 5:313-316

Published Date: 2 November 2010

Improvement of sensorimotor functions in old age by passive sensory stimulation

Tobias Kalisch, Martin Tegenthoff, Hubert R Dinse

Clinical Interventions in Aging 2008, 3:673-690

Published Date: 5 December 2008